BackCalliditas Therapeutics AB Overview

Calliditas Therapeutics AB Long Term Debt

Calliditas Therapeutics AB's long-term debt is $980M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$982.49M
↑ 26.03% YoYΔ $202.92M vs prior year quarter

Peer trimmed avg / median

Loading

Calliditas Therapeutics AB Long Term Debt History

Loading

Calliditas Therapeutics AB vs. peers: Long Term Debt Comparison

Loading

Calliditas Therapeutics AB Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Calliditas Therapeutics AB (CALT) FAQ

As of the most recent data (June 2024), CALT shows a long-term debt of $980M. That compares with $780M in the prior-year period — up 26.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CALT's long-term debt is now $980M (was $780M) — a 26.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Calliditas Therapeutics AB is outperforming or lagging.

Tracking CALT's long-term debt over time shows whether Calliditas Therapeutics AB is scaling, shrinking, or reshaping that part of the business. The current reading is $980M That compares with $780M in the prior-year period — up 26.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Calliditas Therapeutics AB's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $980M) with ownership activity and broader fundamentals.

Calliditas Therapeutics AB's long-term debt is $980M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.